ProCE Banner Activity


Fitting the Puzzle Pieces in Myelodysplastic Syndromes (MDS): A Look at Risk Stratification and Novel Agents

PCE On Demand Live Presentation

Myelodysplastic syndromes (MDS) encompass a heterogeneous group of hematologic clonal malignancies. Treatment of MDS is individualized based on risk assessment. For lower-risk disease, novel therapies are available for anemia management, while management of higher-risk disease focuses on use of hypomethylating agents to slow disease progression and maintain quality of life. This activity provides expert advice on how to assess risk and select optimal treatment regimens for your patients with MDS as well as manage treatment-related adverse events associated with different therapies.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: September 26, 2022

Expiration: September 25, 2023

No longer available for credit.



Kathleen Madden

Kathleen Madden, MSN, ANP-BC, AOCNP

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Sara Tinsley-Vance

Sara Tinsley-Vance, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner and Researcher
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida


This activity is supported by an educational grant from: Taiho Oncology, Inc.

Provided by

ProCE Banner


Taiho Oncology Inc

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify key criteria for diagnosis and risk stratification of patients with MDS

  • Plan treatment strategies for low risk- and higher risk-MDS that incorporate novel agents and combinations

  • Summarize management strategies for adverse events associated with therapies for MDS


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Kathleen Madden, FNP, MSN, AOCNP, APHN: consultant/advisor/speaker: Novartis.

Sara Tinsley-Vance, PhD, MSN, APRN-BC, AOCN: consultant: AbbVie, Bristol-Myers Squibb, CTI Biopharma, Incyte, Taiho Oncology; fees for non-CME/CE services: Astellas, Bristol-Myers Squibb, CTI Biopharma, Incyte.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Kathleen Madden, FNP, MSN, AOCNP, APHN, as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: September 26, 2022
Expiration date: September 25, 2023


On-demand webcast


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Kathleen Madden, FNP, MSN, AOCNP, APHN, Perlmutter Cancer Center, New York, New York

Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 25, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.